Wukun Liu

Dr. Wukun Liu

School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2022 in Chemical Society Reviews
Verified
Journal Article
Closed access
PDF file
YLYunlong Lu
Yunlong Lu
XMXiaoyan Ma
Xiaoyan Ma
XCXingyu Chang
Xingyu Chang
ZLZhenlin Liang
Zhenlin Liang
LLLin Lv
Lin Lv
Wukun LiuWukun Liu
Wukun Liu
Metal complexes have demonstrated significant antitumor activities and platinum complexes are well established in the clinical application of cancer chemotherapy. However, the platinum-based treatment of different types of cancers is massively hampered by severe side effects and resistance development. Consequently, the development of novel metal-based drugs with different mechanism of action and pharmaceutical profile attracts modern medicinal chemists to design and synthesize novel metal-based agents. Among non-platinum anticancer drugs, gold complexes have gained considerable attention due to their significant antiproliferative potency and efficacy. In most situations, the gold complexes exhibit anticancer activities by targeting thioredoxin reductase (TrxR) or other thiol-rich proteins and enzymes and trigger cell death via reactive oxygen species (ROS). Interestingly, gold complexes were recently reported to elicit biochemical hallmarks of immunogenic cell death (ICD) as an ICD inducer. In this review, the recent progress of gold(I) and gold(III) complexes is comprehensively summarized, and their activities and mechanism of action are documented.

9 April 2019 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MBMianli Bian
Mianli Bian
RFRong Fan
Rong Fan
SZSai Zhao
Sai Zhao
Wukun LiuWukun Liu
Wukun Liu

28 May 2022 in Redox Biology
Verified
Journal Article
Open access
ZXZhongren Xu
Zhongren Xu
JXJianqiang Xu
Jianqiang Xu
SSShibo Sun
Shibo Sun
WLWei Lin
Wei Lin
YLYongming Li
Yongming Li
Wukun LiuWukun Liu
Wukun Liu
The nonnegligible reason for the poor prognosis of hepatocellular carcinoma (HCC) is resistance to conventional chemotherapy. Immunogenic cell death (ICD) is a rare immunostimulatory form of cell death that can reengage the tumor-specific immune system. ICD can improve the clinical outcomes of chemotherapeutics by promoting a long-term cancer immunity. The discovery of potential ICD inducers is emerging as a promising direction. In the present study, micheliolide (MCL), a natural guaianolide sesquiterpene lactone, was screened out by the virtual screening strategies, identified as an inhibitor of thioredoxin reductase (TrxR) and was evaluated to have high potential to induce ICD. Here, we showed that MCL induced ICD-associated DAMPs (damage-associated molecular patterns, such as CRT exposure, ATP secretion and HMGB1 release). MCL significantly triggered the regression of established tumors in an immunocompetent mouse vaccine model, and induced ICD (DCs maturation, the stimulation of CD4+, and CD8+ T-cells responses) in vivo. Mechanistically, we found that the magnitude of ICD-associated effects induced upon exposure of HCC cells to MCL was dependent on the generation of reactive oxygen species (ROS)-mediated endoplasmic reticulum stress (ERS). In addition, the suppression of ROS normalized MCL-induced ERS, in contrast, the downregulation of TrxR synergized with the ERS driven by MCL. We also systematically detected the H2O2 generation using Hyper7 sensors in HCC cells exposed to MCL. Notably, MCL inhibited the development of HCC organoids. Collectively, our results reveal a potential association between the TrxR inhibitors and ICD, presenting valuable insights into the MCL-activated ICD in HCC cells.

1 February 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
YSYing Sun
Ying Sun
YLYunlong Lu
Yunlong Lu
MBMianli Bian
Mianli Bian
ZYZhibin Yang
Zhibin Yang
XMXiaoyan Ma
Xiaoyan Ma
Wukun LiuWukun Liu
Wukun Liu

2 November 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
YLYunlong Lu
Yunlong Lu
Wukun LiuWukun Liu
Wukun Liu

17 November 2022 in Pharmacological Research
Verified
Journal Article
Open access
XCXingyu Chang
Xingyu Chang
MBMianli Bian
Mianli Bian
LLLijuan Liu
Lijuan Liu
JYJiaqi Yang
Jiaqi Yang
ZYZhibin Yang
Zhibin Yang
Wukun LiuWukun Liu
Wukun Liu
Traditional platinum-based anticancer drugs, led by cisplatin, play an important role in chemotherapy. However, the development of platinum compounds is limited due to serious toxicity and side effects. In recent years, studies have showed that immunogenic cell death (ICD) may be one of the potential action mechanisms of classical platinum drugs, such as oxaliplatin. This strategy combining chemotherapy and immunotherapy can effectively utilize the body's immune system to help platinum compounds to fight against tumors, and the dose can be appropriately reduced to limit toxic side effects. The induction of ICD by platinum compounds has become a research hotspot and one of the future development directions of metal drugs. Here, the progress of platinum compounds were collected and comprehensively summarized, their capacity of ICD induction and mechanism of action are exposed, providing reference for the design and synthesis of new anticancer platinum ICD inducers.